Bibliografía del artículo
1. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375(9723):1365-1374, 2010.
2. American Diabetes Association. Diagnosis and class?cation of diabetes mellitus. Diabetes Care 35(Suppl 1):S64-S7, 2012.
3. Boyle JP, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics 8:29, 2010.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-Year Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008.
5. Duckworth W, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139, 2009.
6. Reaven PD, et al. Intensive Glucose Lowering Therapy Reduces Cardiovascular Disease Events in VADT Participants with Lower Calcified Coronary Atherosclerosis. Diabetes [published online August 3, 2009].
7. Turnbull FM, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:02288–2298, 2009.
8. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61-6, 2010.
9. Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998.
10. UKPDS: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317:703-713, 1998.
11. Adler AI, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000.
12. Hermida RC, Ayala DE, Mojón A, Fernández JR. In?uence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34:1270-127, 2011.
13. Parati G, et al. Bene?ts of Tight Blood Pressure Control in Diabetic Patients With Hypertension. Importance of early and sustained implementation of effective treatment strategies. Diabetes Care 34 (Suppl. 2):S297-S303, 2011.
14. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575-158, 2010.
15. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818-82, 2011.
16. Ismail-Beigi F, et al. ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419-430, 2010.
17. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233-244, 2010.
18. American Diabetes Association, American College of Cardiology Foundation, American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187-192, 2009.